Skip to main content
Clinical Trials/IRCT20220620055230N1
IRCT20220620055230N1
Completed
Phase 3

A Double blind, Randomized, Comparative study of the Efficacy and Safety of Botulinum Toxin type A Masport with commercial brand Dysport in the treatment of Primary Axillary Hyperhidrosis

Tehran University of Medical Sciences0 sites15 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
15
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults aged between 18 to 65 years who have a sweating rate of 50 mg per minute or higher.

Exclusion Criteria

  • secondary Hyperhidrosis due to systemic problems.
  • people who have taken Aminoglycosides in the last three weeks.
  • people who have had botulinum toxin injection in the past year.
  • people with Neuromuscellar diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials